Skip to content

Study · Randomized controlled trial · n = 44 · 2020

3 results

Pain-modulating effects of oxytocin in patients with chronic low back pain.

Boll S, Ueltzhoeffer K, Roth C, Bertsch K, Desch S, Nees F, Grinevich V, Herpertz SC

Neuropharmacology13 Apr 2020Cited by 12 (Europe PMC)

PMID32298704 (opens in a new tab)DOI10.1016/j.neuropharm.2020.108105 (opens in a new tab)PepBankPUB-32298704
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In male patients with chronic low back pain versus healthy controls, intranasal oxytocin attenuated heat pain intensity ratings versus placebo.

    In plain wordsIn men with chronic low back pain, oxytocin lowered heat pain ratings compared with placebo, relative to healthy men.

    Peptide
    Oxytocin
    Outcome
    DecreaseHeat pain intensity ratings
    Study

    n = 44

    Comparator
    Placebo
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    During heat pain processing we found that OT versus PL attenuated pain intensity ratings and increased BOLD responses in the caudate nucleus of the striatum in CBP versus HCs.
    1 context sentence
    Summary · context
    we conducted an exploratory, randomized, placebo-controlled, cross-over study to examine effects of intranasal OT in male patients suffering from chronic low back pain (CBP) versus healthy controls (HC).
  2. 02HumanRandomized controlled trialMechanism

    In male patients with chronic low back pain versus healthy controls, intranasal oxytocin increased caudate nucleus BOLD responses during heat pain versus placebo.

    In plain wordsIn men with chronic low back pain, oxytocin increased brain activity in the caudate nucleus during heat pain compared with placebo, relative to healthy men.

    Peptide
    Oxytocin
    Outcome
    IncreaseCaudate nucleus BOLD response during heat pain
    Study

    n = 44

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    During heat pain processing we found that OT versus PL attenuated pain intensity ratings and increased BOLD responses in the caudate nucleus of the striatum in CBP versus HCs.
    1 context sentence
    Summary · context
    we conducted an exploratory, randomized, placebo-controlled, cross-over study to examine effects of intranasal OT in male patients suffering from chronic low back pain (CBP) versus healthy controls (HC).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In male patients with chronic low back pain, intranasal oxytocin had no observed effect on spontaneously experienced pain versus placebo.

    In plain wordsIn men with chronic low back pain, oxytocin did not change spontaneous back pain compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSpontaneous back pain in chronic low back pain
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    However, we did not observe OT effects on spontaneously experienced pain in CBP patients.
    1 context sentence
    Summary · context
    we conducted an exploratory, randomized, placebo-controlled, cross-over study to examine effects of intranasal OT in male patients suffering from chronic low back pain (CBP) versus healthy controls (HC).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.